Dr. Klaus Gottlieb joins Synthetic Biologics leadership team

Klaus Gottlieb, MD, FACG, has joined Synthetic Biologics as its vice president of clinical and regulatory affairs.

Prior to joining Synthetic Biologics, Dr. Gottlieb was the senior medical director of therapeutic strategy – gastroenterology at Fortune 500 company Quintiles, according to the report.

Dr. Gottlieb will provide further leadership support as Synthetic Biologics moves forward with Phase 2 clinical trials for its irritable bowel syndrome and Clostridium difficile products.

He will report directly to Joseph Sliman, MD, MPH, senior vice president of clinical and regulatory affairs.

More articles on gastroenterology:
Lovell Federal Health Care Center opens new GI center
5 most-read GI/endoscopy stories – May 25 to May 29
13 GI physicians making headlines – May 26, 2015

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers